February 2026 - WorkMarkets

February 2026 Portfolio Close: Why I Doubled Down on MSFT, NFLX, and CSU Amidst Market Volatility

Amadeu / 02/28/2026

In February 2026, my February 2026 Portfolio underwent a strategic consolidation, emphasizing high-growth resilience. I increased positions in Microsoft (MSFT), Netflix (NFLX), and Constellation Software (CSU.TO), leveraging sector-specific volatility. While Bitcoin faced a -28% correction and Novo Nordisk retraced -22%, Netflix led with a +17.2% return. My strategy remains anchored in tiered entries and a […]

Market News

NVIDIA in 2026: Record-Breaking Results and an 18 P/E — The Crossroads of Dominance and Cyclicality

Amadeu / 02/26/2026

NVIDIA’s Q4 FY26 results confirm its absolute leadership in AI infrastructure, posting record revenue of $68.1 billion (+73% YoY) and net income of $43 billion. Despite a forward P/E of 18 for 2027, which appears to be a historic discount relative to growth, the absence of revenue from China and the potential cyclicality of software

Strategies

The Great AI Purge of 2026: Why Capex Fear and Obsolescence Paranoia Are Creating the Decade’s Best Opportunities?

Amadeu / 02/24/2026

In February 2026, financial markets are undergoing an irrational capitulation driven by AI-induced fear. While Big Tech (Microsoft, Amazon) is being penalized for a projected $650 billion Capex, software and service giants (Adobe, Visa, Booking) are plummeting on fears of technical obsolescence. However, Goldman Sachs data suggests that operational efficiency and new revenue streams from

Investment Portfolio

Sprouts Farmers Market (SFM): Generational Opportunity or Value Trap? Why I Initiated a Position After the 64% Correction

Amadeu / 02/24/2026

Sprouts Farmers Market (SFM) is a dominant player in the health-focused grocery niche. With $8.8 billion in revenue in 2025 and 7.3% comparable store sales growth, the company operates with solid margins and aggressive share buybacks. Currently, following a 64% technical correction from its 2025 highs, SFM trades at a forward P/E of 11x, presenting

Market News

Novo Nordisk in Free Fall: A Generational Opportunity or the End of Obesity Hegemony?

Amadeu / 02/24/2026

Novo Nordisk (NVO) shares plummeted over 21% in 48 hours following REDEFINE 4 trial data, where CagriSema showed a 23% weight loss compared to Eli Lilly’s Zepbound at 25.5%. Despite the market’s knee-jerk reaction, fundamental analysis reveals a 2026 P/E of 11x, a massive discount compared to Lilly’s 30x. With a robust pipeline including oral

Investment Portfolio

The 2026 Portfolio State of Play: Why My “Resilient Growth” Strategy Is Ignoring the Market Noise

Amadeu / 02/22/2026

As of February 2026, my portfolio state of play centers on a strategic pivot toward long-term fixed income (41.3% in US Treasuries) and high-quality technology (MSFT). Diversified across defensive sectors (GIS) and luxury (RACE), the portfolio prioritizes “moat-heavy” firms with sustainable EPS growth. I am currently capitalizing on the software sector correction and the divergence